Paul Peter Tak
Kintai Therapeutics, USA
Paul Peter Tak, MD PhD FMedSci is President & CEO of Kintai Therapeutics.
He was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). He published > 550 papers (H index 126 [Google Scholar]).
At GlaxoSmithKline he was Senior Vice President, Chief Immunology Officer, and Global Development Leader.
He has been CEO of Tempero Pharmaceuticals, and board member of Galvani Bioelectronics and ViiV Healthcare. He is currently board director of Sitryx Therapeutics, Kintai Therapeutics, Levicept and Omega Therapeutics.